An advocate general (AG) has said that regulatory authorities in “concerned” EU member states handling drug marketing authorisations (MAs) are co-responsible for approved documents on data exclusivity.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Advocate general, data exclusivity, CJEU, Court of Justice of the European Union, Helm, Astellas, medicine, marketing authorisation
